Chemotherapy alone for organ preservation in advanced laryngeal cancer

Vasu Divi, Francis P. Worden, Mark E. Prince, Avraham Eisbruch, Julia S. Lee, Carol R. Bradford, Douglas B. Chepeha, Theodoros N. Teknos, Norman D. Hogikyan, Jeffrey S. Moyer, Christina I. Tsien, Susan G. Urba, Gregory T. Wolf

Research output: Contribution to journalArticlepeer-review


Background. For patients with advanced laryngeal cancer, a trial was designed to determine if chemotherapy alone, in patients achieving a complete histologic complete response after a single neoadjuvant cycle, was an effective treatment with less morbidity than concurrent chemoradiotherapy. Methods. Thirty-two patients with advanced laryngeal or hypopharyngeal cancer received 1 cycle of induction chemotherapy, and subsequent treatment was decided based on response. Results. A histologic complete response was achieved in 4 patients and were treated with chemotherapy alone. All 4 patients' cancer relapsed in the neck and required surgery and postoperative radiotherapy (RT). Twenty-five patients were treated with concomitant chemoradiation. Three patients were treated with surgery. Overall survival and disease-specific survival at 3 years were 68% and 78%, respectively. Conclusion. Chemotherapy alone is not feasible for long-term control of regional disease in patients with advanced laryngeal cancer even when they achieve a histologic complete response at the primary site.

Original languageEnglish (US)
Pages (from-to)1040-1047
Number of pages8
JournalHead and Neck
Issue number8
StatePublished - Aug 2010
Externally publishedYes


  • Chemotherapy
  • Clinical outcomes
  • Head and neck neoplasms
  • Laryngeal cancer
  • Organ preservation

ASJC Scopus subject areas

  • Otorhinolaryngology

Fingerprint Dive into the research topics of 'Chemotherapy alone for organ preservation in advanced laryngeal cancer'. Together they form a unique fingerprint.

Cite this